Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study

NCT04314297 is registered in ClinicalTrials.gov with Union Hospital, Tongji Medical College, Huazhong University of Science and Technology as lead sponsor.

NCT NCT04314297
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04314297 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study
Lead sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase
Phase 2
Overall status
Unknown status
Start date
April 30, 2020
Completion date
February 28, 2022
Enrollment
33 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

anlotinib, durvalumab, small cell lung cancer